CEO Total Pay
$10.0M
FY2021 Summary Compensation, above median
CARA FY2021 SEC EDGAR DEF 14A
Tvardi Therapeutics, Inc. CEO pay ratio
The CEO earned $10.0M in FY2021 against median worker pay of $192,240 · Chemicals & Pharmaceuticals.
- State
- DE
- Filing date
- 2022-04-22
- Industry
- Chemicals & Pharmaceuticals
- Fiscal year
- FY2021
Data updated August 2026
Subscribe to Tvardi Therapeutics, Inc. CEO pay filing updates (RSS)
CEO-to-worker pay ratio
52:1
Moderate (Scale: 0–1000:1)
CEO pay
$10.0M
Median worker
$192,240
Latest filing FY2021. This company's newest DEF 14A on file is for FY2021, not FY2025, so the figures on this page are from that earlier year and are not ranked against the FY2025 industry benchmark. Industry pages mark issuers like this one with a "Latest filing" label.
Answer first
Tvardi Therapeutics, Inc. reported a 52:1 CEO-to-worker pay ratio in FY2021 - above the Chemicals & Pharmaceuticals median of 42:1 across 168 filers.
Figures come from Section 953(b) Dodd-Frank DEF 14A disclosures - not estimates. View all Chemicals & Pharmaceuticals companies.
- Pay ratio
- 52:1
- FY2021 disclosed
- CEO total
- $10.0M
- Summary Compensation Table total
- Median worker
- $192,240
- Dodd-Frank median employee
Ratio bands among Chemicals & Pharmaceuticals peers
Exclusive CEO-to-median-worker bands across 153 complete latest-FY filings in SIC 28. Segments sum to the peer set, not this company's compensation pillar.
CEO Compensation Breakdown, FY2021
A component-level pay breakdown is not reported in Tvardi Therapeutics, Inc.'s structured SEC pay-ratio disclosure. See our methodology →
Industry Comparison - Chemicals & Pharmaceuticals
This Company's Ratio
52:1
Industry Median Ratio
42:1
Industry Median CEO Pay
$7.9M
This CEO's Pay
$10.0M
Companies in Industry
168
vs. Industry Median
Above
Tvardi Therapeutics, Inc.: MODEST · HEAVY pay ratio
Tvardi Therapeutics, Inc. disclosed 52:1 CEO-to-worker pay and $10.0M CEO total in FY2021. the CEO earned 52× the median employee ($192,240) in FY2021.
Median employee $192,240 (ELITE-MED); MODEST · HEAVY stamps put about 52 median-wage years per CEO year.
Pay Ratio
52:1
Near industry median
What FY2021 shows for Tvardi Therapeutics, Inc.
Tvardi Therapeutics, Inc. disclosed 52:1 CEO-to-worker pay and $10.0M CEO total in FY2021. The structured pay-ratio disclosure reports the total without line-item components. Chemicals & Pharmaceuticals (SIC 28) median ratio is 42:1 across 168 FY2025 filers; Tvardi Therapeutics, Inc.'s $10.0M CEO total is above the $7.9M industry median CEO pay.
Tvardi Therapeutics, Inc. stamps MODEST · HEAVY · ELITE-MED; grant-date fair value (not realized pay) is what the DEF 14A reports. Open Chemicals & Pharmaceuticals peers.
Key Data, FY2021
- Total Compensation
- $10.0M
- Median Employee Pay
- $192,240
- Pay Ratio
- 52:1
- Filing Date
- 2022-04-22
Company Info
- Ticker
- CARA
- CIK
- 1346830
- Industry
- Chemicals & Pharmaceuticals
- SIC Code
- 2834
- State
- DE
SEC EDGAR DEF 14A for CIK 1346830, FY2021. Informational only, not investment advice. Verify on EDGAR.
Read our methodology - how this data is sourced, computed, and verified. Tvardi Therapeutics, Inc. disclosed 52:1 CEO-to-worker pay and $10.0M CEO total in FY2021.
Read with Tvardi Therapeutics, Inc.
ABS(ceo_total_comp) peers first, then a SIC pole and a stamp-branched guide - not a fixed Related strip. This page stamps MODEST · HEAVY · ELITE-MED.
Sba Communications Corp · HEAVY
ABS(ceo_total_comp) peer at $10.0M (Δ $1K lighter vs Tvardi Therapeutics, Inc.); MID · HIGH-MED vs this page's MODEST · HEAVY · ELITE-MED.
Cedar Fair L P · HEAVY
ABS(ceo_total_comp) peer at $10.0M (Δ $6K lighter vs Tvardi Therapeutics, Inc.); EXTREME · LOW-MED vs this page's MODEST · HEAVY · ELITE-MED.
Amicus Therapeutics, Inc. · HEAVY
ABS(ceo_total_comp) peer at $10.0M (Δ $6K lighter vs Tvardi Therapeutics, Inc.); MODEST · ELITE-MED vs this page's MODEST · HEAVY · ELITE-MED.
Kontoor Brands, Inc. · HEAVY
ABS(ceo_total_comp) peer at $10.0M (Δ $17K lighter vs Tvardi Therapeutics, Inc.); MEGA · LOW-MED vs this page's MODEST · HEAVY · ELITE-MED.
Chemicals & Pharmaceuticals benchmark
Tvardi Therapeutics, Inc. stamps MODEST · HEAVY · ELITE-MED inside SIC 28 - open the industry median board after the ABS peers.
Pay-ratio rankings · MODEST
See where MODEST · HEAVY packages sit on the national leaderboard after reading Tvardi Therapeutics, Inc..
Ratio primer · MODEST
Tvardi Therapeutics, Inc.'s MODEST stamp sits in the lower Item 402(u) band - start with how the ratio is disclosed before comparing peers.
Data sourced from SEC EDGAR DEF 14A for Tvardi Therapeutics, Inc. (CIK 1346830), FY2021. See our methodology. Aggregated by PlainCEOPay as of August 2026.
Data currency: Executive compensation from SEC EDGAR DEF 14A proxy statements through fiscal year 2025, compiled and last refreshed August 2026. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.